摘要
目的:探讨低分子肝素对不稳定心绞痛的临床疗效及安全性。方法:将166例患者按入选顺序随机分为常规治疗组和低分子肝素组。常规治疗组接受常规治疗,低分子肝素组在常规治疗组的基础上加低分子肝素。结果:与对照组相比,治疗组患者心绞痛发作次数、硝酸甘油用量、心电图情况明显改善。治疗前后凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)及血小板计数(PLT)无统计学差异。结论:低分子肝素治疗不稳定心绞痛有效,且不良反应少。
Objective:To study the efficacy and safety of Nadroparin calcium on patients with unstable angina pectoris based on routine therapies. Methods: 166 cases of unstable angina pectoris were randomly divided into two groups: General group was 81 cases with routine therapy. Nadroparin calcium group was 85 cases who were give Nadroparin calcium n with besides routine therapy. Results: Compared with the General group, the effects of the drugs on frequency of angina attacks ,daily dose of nitroglyccrin and electrocardiogram ST segment were improved. Plasma PT,APTT,and PLT of pretreatment and posttreatment had no significant difference. Conclusions: Nadroparin calcium in treatment of unstable angina pectoris has shown effectiveness and safety. There is no significance and difference inside reaction between the two groups.
出处
《中国民康医学》
2009年第15期1801-1802,共2页
Medical Journal of Chinese People’s Health
关键词
低分子肝素
不稳定心绞痛
Nadroparin calcium
Unstable angina pectoris